{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:13:53Z","timestamp":1788966833475,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["422179811"],"award-info":[{"award-number":["422179811"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00406-022-01532-3","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:03:06Z","timestamp":1672131786000},"page":"1477-1487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neurosteroids and translocator protein 18\u00a0kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-9062","authenticated-orcid":false,"given":"Rainer","family":"Rupprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit Kumar","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Kufner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nothdurfter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schwarzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rammes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/ijnp\/pyz062","volume":"23","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y et al (2020) Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. Int J Psychopharmacol 23:76\u201387. https:\/\/doi.org\/10.1093\/ijnp\/pyz062","journal-title":"Int J Psychopharmacol"},{"key":"1532_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12788\/acp.0048","volume":"34","author":"MD Kritzer","year":"2022","unstructured":"Kritzer MD, Mischel NA, Young JR, Lai CS, Masand PS, Szabo ST et al (2022) Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress. Ann Clin Psychiatry 34:33\u201343. https:\/\/doi.org\/10.12788\/acp.0048","journal-title":"Ann Clin Psychiatry"},{"key":"1532_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091809","author":"O Saiz-Vazquez","year":"2021","unstructured":"Saiz-Vazquez O, Gracia-Garcia P, Ubillos-Landa S, Puente-Martinez A, Casado-Yusta S, Olaya B, Santabarbara J (2021) Depression as a risk factor for Alzheimer\u2019s disease: a systematic review of longitudinal meta-analyses. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10091809","journal-title":"J Clin Med"},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","volume":"30","author":"A Pariente","year":"2016","unstructured":"Pariente A, de Gage SB, Moore N, B\u00e9gaud B (2016) The benzodiazepine\u2013dementia disorders link: current state of knowledge. CNS Drugs 30:1\u20137. https:\/\/doi.org\/10.1007\/s40263-015-0305-4","journal-title":"CNS Drugs"},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18:37\u201348. https:\/\/doi.org\/10.2165\/00023210-200418010-00004","journal-title":"CNS Drugs"},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WAD.0000000000000099","volume":"30","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhou X, Meranus DH, Wang L, Kukull WA (2016) Benzodiazepine use and cognitive decline in elderly with normal cognition. Alzheimer Dis Assoc Disord 30:113\u2013117. https:\/\/doi.org\/10.1097\/WAD.0000000000000099","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","volume":"27","author":"V Papadopoulos","year":"2006","unstructured":"Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacap\u00e8re JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR et al (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402\u2013409. https:\/\/doi.org\/10.1016\/j.tips.2006.06.005","journal-title":"Trends Pharmacol Sci"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd3295","volume":"9","author":"R Rupprecht","year":"2010","unstructured":"Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N et al (2010) Translocator protein (18 kDa) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9:971\u2013988. https:\/\/doi.org\/10.1038\/nrd3295","journal-title":"Nat Rev Drug Discov"},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15622975.2021.1961503","volume":"10","author":"R Rupprecht","year":"2021","unstructured":"Rupprecht R, Rupprecht C, Rammes G (2021) Neuroinflammation and psychiatric disorders: relevance of C1q, translocator protein (18kDa) (TSPO), and neurosteroids. World J Biol Psychiatry 10:1\u20137. https:\/\/doi.org\/10.1080\/15622975.2021.1961503","journal-title":"World J Biol Psychiatry"},{"key":"1532_CR10","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1073\/pnas.1502670112","volume":"112","author":"J Fan","year":"2015","unstructured":"Fan J, Campioli E, Midzak A, Culty M, Papadopoulos V (2015) Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proc Natl Acad Sci USA 112:7261\u20137266. https:\/\/doi.org\/10.1073\/pnas.1502670112","journal-title":"Proc Natl Acad Sci USA"},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1210\/me.2015-1033","volume":"2","author":"V Selvaraj","year":"2015","unstructured":"Selvaraj V, Stocco DM, Tu LN (2015) Minireview: translocator protein (TSPO) and steroidogenesis: a reappraisal. Mol Endocrinol 2:490\u2013501. https:\/\/doi.org\/10.1210\/me.2015-1033","journal-title":"Mol Endocrinol"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00213-005-2247-x","volume":"181","author":"S Pini","year":"2005","unstructured":"Pini S, Martini C, Abelli M, Muti M, Gesi C, Montali M, Chelli B, Lucacchini A, Cassano GB (2005) Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology 181:407\u2013411. https:\/\/doi.org\/10.1007\/s00213-005-2247-x","journal-title":"Psychopharmacology"},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000315440","volume":"62","author":"M Abelli","year":"2010","unstructured":"Abelli M, Chelli B, Costa B, Lari L, Cardini A, Gesi C, Muti M, Lucacchini A, Martini C, Cassano GB et al (2010) Reductions in platelet 18-kDa translocator protein density are associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 62:98\u2013103. https:\/\/doi.org\/10.1159\/000315440","journal-title":"Neuropsychobiology"},{"key":"1532_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-0042-107795","volume":"49","author":"N Sarubin","year":"2016","unstructured":"Sarubin N, Baghai TC, Lima-Ojeda JM, Melchner D, Hallof-Buestrich H, Wolf L, Hilbert S, Milenkovic VM, Wetzel CH, Rupprecht R et al (2016) Translocator protein (TSPO) expression in platelets of depressed patients decreases during antidepressant therapy. Pharmacopsychiatry 49:204\u2013209. https:\/\/doi.org\/10.1055\/s-0042-107795","journal-title":"Pharmacopsychiatry"},{"key":"1532_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamapsychiatry.2014.2427","volume":"72","author":"E Setiawan","year":"2015","unstructured":"Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72:268\u2013265. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2427","journal-title":"JAMA Psychiatry"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jamapsychiatry.2017.1567","volume":"74","author":"S Attwells","year":"2017","unstructured":"Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ et al (2017) Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry 74:833\u2013840. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1567","journal-title":"JAMA Psychiatry"},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.biopsych.2020.03.007","volume":"88","author":"S Attwells","year":"2020","unstructured":"Attwells S, Setiawan E, Rusjan OM, Xu C, Hutton C, Rafiei D, Varughese B, Kahn A, Kish SJ, Vasdev N (2020) Translocator protein distribution volume predicts reductions of symptoms during open-label trial of celecoxib in major depressive disorder. Biol Psychiatry 88:649\u2013656. https:\/\/doi.org\/10.1016\/j.biopsych.2020.03.007","journal-title":"Biol Psychiatry"},{"key":"1532_CR18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/cells9091941","volume":"9","author":"BB Tournier","year":"2020","unstructured":"Tournier BB, Tsartsalis S, Ceyzeriat K, Garibotto V, Millet P (2020) In vivo TSPO signal and neuroinflammation in Alzheimer\u00b4s disease. Cells 9:1941. https:\/\/doi.org\/10.3390\/cells9091941","journal-title":"Cells"},{"key":"1532_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jad.2018.08.021","volume":"241","author":"H Li","year":"2018","unstructured":"Li H, Sagar AP, Keri S (2018) Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J Affect Disord 241:305\u2013310. https:\/\/doi.org\/10.1016\/j.jad.2018.08.021","journal-title":"J Affect Disord"},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41380-020-0745-1","volume":"26","author":"T Notter","year":"2021","unstructured":"Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K et al (2021) Neuronal activity increases translocator protein (TSPO) levels. Mol Psychiatry 26:2025\u20132037. https:\/\/doi.org\/10.1038\/s41380-020-0745-1","journal-title":"Mol Psychiatry"},{"key":"1532_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/YPG.0b013e32832080f6","volume":"19","author":"B Costa","year":"2009","unstructured":"Costa B, Pini S, Martini C, Abelli M, Gabelloni P, Landi S et al (2009) Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatr Genet 19:110\u2013111. https:\/\/doi.org\/10.1097\/YPG.0b013e32832080f6","journal-title":"Psychiatr Genet"},{"key":"1532_CR22","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1016\/j.psyneuen.2013.07.007","volume":"38","author":"A Colasanti","year":"2013","unstructured":"Colasanti A, Owen DR, Grozeva D, Rabiner EA, Matthews PM, Craddock N et al (2013) Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18 kDa translocator protein (TSPO). Psychoneuroendocrinology 38:2826\u20132829. https:\/\/doi.org\/10.1016\/j.psyneuen.2013.07.007","journal-title":"Psychoneuroendocrinology"},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.psyneuen.2018.01.013","volume":"89","author":"AR Prossin","year":"2018","unstructured":"Prossin AR, Chandler M, Ryan KA, Saunders F, Kamali M, Papadopoulos V et al (2018) Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder. Psychoneuroendocrinology 89:194\u2013202. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.01.013","journal-title":"Psychoneuroendocrinology"},{"key":"1532_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D, Br\u00fcnig I, Benson JA, Fritschiy JM et al (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acic(A) receptor subtypes. Nature 401:796\u2013800. https:\/\/doi.org\/10.1038\/44579","journal-title":"Nature"},{"key":"1532_CR25","doi-asserted-by":"publisher","first-page":"e3000157","DOI":"10.1371\/journal.pbio.3000157","volume":"17","author":"ZW Chen","year":"2019","unstructured":"Chen ZW, Bracamontes JR, Budelier MM, Germann AL, Shin DJ, Kathiresan K et al (2019) Multiple functional neurosteroid binding sites on GABAA receptors. PLoS Biol 17:e3000157. https:\/\/doi.org\/10.1371\/journal.pbio.3000157","journal-title":"PLoS Biol"},{"key":"1532_CR26","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1111\/bph.13843","volume":"174","author":"A Locci","year":"2017","unstructured":"Locci A, Pinna G (2017) Neurosteroid biosynthesis down-regulation and changes in GABA(A) receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. Br J Pharmacol 174:3226\u20133241. https:\/\/doi.org\/10.1111\/bph.13843","journal-title":"Br J Pharmacol"},{"key":"1532_CR27","doi-asserted-by":"publisher","first-page":"110215","DOI":"10.1016\/j.ynstr.2020.100215","volume":"14","author":"SM Paul","year":"2020","unstructured":"Paul SM, Pinna G, Guidotti A (2020) Allopregnanolone: from molecular pathophysiology to therapeutics: a historical perspective. Neurobiol Stress 14:110215. https:\/\/doi.org\/10.1016\/j.ynstr.2020.100215","journal-title":"Neurobiol Stress"},{"key":"1532_CR28","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1016\/j.neuropharm.2020.108333","volume":"181","author":"AL Althaus","year":"2020","unstructured":"Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Mogdil A, Davies PA, Moss SJ et al (2020) Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology 181:10833. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333","journal-title":"Neuropharmacology"},{"key":"1532_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neubiorev.2012.10.005","volume":"37","author":"CF Zorumski","year":"2013","unstructured":"Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109\u2013122. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.10.005","journal-title":"Neurosci Biobehav Rev"},{"key":"1532_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0306-4530(02)00064-1","volume":"28","author":"R Rupprecht","year":"2003","unstructured":"Rupprecht R (2003) Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139\u2013168. https:\/\/doi.org\/10.1016\/s0306-4530(02)00064-1","journal-title":"Psychoneuroendocrinology"},{"key":"1532_CR31","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41380-022-01561-3","volume":"27","author":"R Rupprecht","year":"2022","unstructured":"Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID (2022) Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry 27:2918\u20132926. https:\/\/doi.org\/10.1038\/s41380-022-01561-3","journal-title":"Mol Psychiatry"},{"key":"1532_CR32","doi-asserted-by":"publisher","first-page":"13512","DOI":"10.1073\/pnas.96.23.13512","volume":"96","author":"LD Griffin","year":"1999","unstructured":"Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96:13512\u201313517. https:\/\/doi.org\/10.1073\/pnas.96.23.13512","journal-title":"Proc Natl Acad Sci USA"},{"key":"1532_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/sj.mp.4001782","volume":"11","author":"C Sch\u00fcle","year":"2006","unstructured":"Sch\u00fcle C, Romeo E, Uzunov DP, Eser D, di Michele F, Baghai TC et al (2006) Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydoxysteroid oxidoreductase activity. Mol Psychiatry 11:261\u2013272. https:\/\/doi.org\/10.1038\/sj.mp.4001782","journal-title":"Mol Psychiatry"},{"key":"1532_CR34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1176\/ajp.155.7.910","volume":"155","author":"E Romeo","year":"1998","unstructured":"Romeo E, Str\u00f6hle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155:910\u2013913. https:\/\/doi.org\/10.1176\/ajp.155.7.910","journal-title":"Am J Psychiatry"},{"key":"1532_CR35","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","volume":"95","author":"V Uzunova","year":"1998","unstructured":"Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E et al (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl Acad Sci USA 95:3239\u20133244. https:\/\/doi.org\/10.1073\/pnas.95.6.3239","journal-title":"Proc. Natl Acad Sci USA"},{"key":"1532_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/archpsyc.60.2.161","volume":"60","author":"A Str\u00f6hle","year":"2003","unstructured":"Str\u00f6hle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewski G, Holsboer F, Rupprecht R (2003) Induced panic attacks shift GABA(A) receptor modulatory steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60:161\u2013168. https:\/\/doi.org\/10.1001\/archpsyc.60.2.161","journal-title":"Arch Gen Psychiatry"},{"key":"1532_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2007.05.006","volume":"116","author":"SS Girdler","year":"2007","unstructured":"Girdler SS, Klatzkin R (2007) Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol Ther 116:125\u2013139. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.05.006","journal-title":"Pharmacol Ther"},{"key":"1532_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000358838","volume":"69","author":"C Hellgren","year":"2014","unstructured":"Hellgren C, \u00c5kerud H, Skalkidou A, B\u00e4ckstr\u00f6m T, Sundstr\u00f6m-Poromaa I (2014) Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology 69:147\u2013153. https:\/\/doi.org\/10.1159\/000358838","journal-title":"Neuropsychobiology"},{"key":"1532_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","volume":"59","author":"J Maguire","year":"2008","unstructured":"Maguire J, Mody I (2008) GABA(A)R plasticity during pregnancy: relevance to post-partum depression. Neuron 59:207\u2013213. https:\/\/doi.org\/10.1016\/j.neuron.2008.06.019","journal-title":"Neuron"},{"key":"1532_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","volume":"73","author":"SG Brickley","year":"2012","unstructured":"Brickley SG, Mody I (2012) Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 73:23\u201334. https:\/\/doi.org\/10.1016\/j.neuron.2011.12.012","journal-title":"Neuron"},{"key":"1532_CR41","doi-asserted-by":"publisher","first-page":"823616","DOI":"10.3389\/fgwh.2022.823616","volume":"3","author":"G Pinna","year":"2022","unstructured":"Pinna G, Almeida FB, Davis JM (2022) Allopregnanolone in postpartum depression. Front Glob Womens Health 3:823616. https:\/\/doi.org\/10.3389\/fgwh.2022.823616","journal-title":"Front Glob Womens Health"},{"key":"1532_CR42","doi-asserted-by":"publisher","first-page":"104827","DOI":"10.1016\/j.psyneuen.2020.104827","volume":"121","author":"KM Deligiannidis","year":"2020","unstructured":"Deligiannidis KM, Kroll-Desrosiers AR, Tan Y, Dubuke ML, Shaffer SA (2020) Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis. Psychoneuroendocrinology 121:104827. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104827","journal-title":"Psychoneuroendocrinology"},{"key":"1532_CR43","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00213-016-4258-1","volume":"233","author":"E Timby","year":"2016","unstructured":"Timby E, B\u00e4ckstr\u00f6m T, Nyberg S, Stenlund H, Wihlb\u00e4ck AN, Bixo M (2016) Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology 233:2109\u20132117. https:\/\/doi.org\/10.1007\/s00213-016-4258-1","journal-title":"Psychopharmacology"},{"key":"1532_CR44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.1175055","volume":"325","author":"R Rupprecht","year":"2009","unstructured":"Rupprecht R, Rammes G, Eser D, Baghai TC, Sch\u00fcle C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F et al (2009) Translocator protein (18 kDa) as target for anxiolytics without benzodiazepine-like side effects. Science 325:490\u2013493. https:\/\/doi.org\/10.1126\/science.1175055","journal-title":"Science"},{"key":"1532_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12035-020-02136-5","volume":"58","author":"AM Barron","year":"2021","unstructured":"Barron AM, Higuchi M, Hattori S, Kito S, Suhara T, Ji B (2021) Regulation of anxiety and depression by mitochondrial translocator protein-mediated steroidogenesis: the role of neurons. Mol Neurobiol 58:550\u2013563. https:\/\/doi.org\/10.1007\/s12035-020-02136-5","journal-title":"Mol Neurobiol"},{"key":"1532_CR46","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s11064-020-03036-9","volume":"45","author":"P Ren","year":"2020","unstructured":"Ren P, Ma L, Wang JY, Guo H, Sun L, Gao ML, Liu YZ, Ma YQ, Li FY, Guo WZ (2020) Anxiolytic and anti-depressive like effects of translocator protein (18 kDa) ligand YL-IPAo8 in a rat model of postpartum depression. Neurochem Res 45:1746\u20131757. https:\/\/doi.org\/10.1007\/s11064-020-03036-9","journal-title":"Neurochem Res"},{"key":"1532_CR47","doi-asserted-by":"publisher","first-page":"107835","DOI":"10.1016\/j.neuropharm.2019.107835","volume":"162","author":"K Nozaki","year":"2020","unstructured":"Nozaki K, Ito H, Ohgidani M, Yamawaki Y, Sahin EH, Kitajima T, Katsumata S, Yamawaki S, Kato TA, Aizawa H (2020) Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress. Neuropharmacology 162:107835. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107835","journal-title":"Neuropharmacology"},{"key":"1532_CR48","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.phrs.2019.04.034","volume":"145","author":"C Mattei","year":"2019","unstructured":"Mattei C, Taly A, Soualah Z, Sauleis O, Herrison D, Guerineau NC, Verleye M, Legros C (2019) Involvement of the GABA(A) receptor \u03b1 subunit in the mode of action of etifoxine. Pharmacol Res 145:104250. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.034","journal-title":"Pharmacol Res"},{"key":"1532_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuropharm.2019.107835","volume":"21","author":"N Nguyen","year":"2006","unstructured":"Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139\u2013149. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107835","journal-title":"Hum Psychopharmacol"},{"key":"1532_CR50","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1007\/s00213-020-05617-6","volume":"237","author":"B Vincente","year":"2020","unstructured":"Vincente B, Saldicia S, Hormazabal N, Bustos C, Rubi P (2020) Etifoxine is non-inferior than clonazepam for the reduction of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology 237:3357\u20133367. https:\/\/doi.org\/10.1007\/s00213-020-05617-6","journal-title":"Psychopharmacology"},{"key":"1532_CR51","doi-asserted-by":"publisher","first-page":"173321","DOI":"10.1016\/j.pbb.2021.173321","volume":"213","author":"JM Witkin","year":"2022","unstructured":"Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A et al (2022) The imidazodiazepine, KRM-II-81: an example of a newly emerging generations of GABAkines for neurological and psychiatric disorders. Phamacol Biochem Behav 213:173321. https:\/\/doi.org\/10.1016\/j.pbb.2021.173321","journal-title":"Phamacol Biochem Behav"},{"key":"1532_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/neuro.06.004.2008","volume":"2","author":"N Kriegeskorte","year":"2008","unstructured":"Kriegeskorte N, Mur M, Bandettini PA (2008) Representational similarity analysis-connecting the branches of systems neuroscience. Front Syst Neurosci 2:4. https:\/\/doi.org\/10.3389\/neuro.06.004.2008","journal-title":"Front Syst Neurosci"},{"key":"1532_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/scan\/nsx147","volume":"13","author":"SM Levine","year":"2018","unstructured":"Levine SM, Pfaller M, Reichenberger J, Shiban Y, M\u00fchlberger A, Rupprecht R, Schwarzbach JV (2018) Relating experimentally-induced fear to pre-existing phobic fear in the human brain. Soc Cogn Affect Neurosci 13:64\u2013172. https:\/\/doi.org\/10.1093\/scan\/nsx147","journal-title":"Soc Cogn Affect Neurosci"},{"key":"1532_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10083-6","volume":"10","author":"MA Thornton","year":"2019","unstructured":"Thornton MA, Weaverdyck ME, Mildner JN, Tamir DI (2019) People represent their own mental states more distinctly than those of others. Nat Commun 10:1\u20139. https:\/\/doi.org\/10.1038\/s41467-019-10083-6","journal-title":"Nat Commun"},{"key":"1532_CR55","doi-asserted-by":"publisher","first-page":"10687","DOI":"10.1073\/pnas.0802631105","volume":"105","author":"C Kemp","year":"2008","unstructured":"Kemp C, Tenenbaum JB (2008) The discovery of structural form. Proc Natl Acad Sci USA 105:10687\u201310692. https:\/\/doi.org\/10.1073\/pnas.0802631105","journal-title":"Proc Natl Acad Sci USA"},{"key":"1532_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuropsychologia.2018.10.008","volume":"120","author":"SM Levine","year":"2018","unstructured":"Levine SM, Wackerle A, Rupprecht R, Schwarzbach JV (2018) The neural representation of an individualized relational affective space. Neuropsychologia 120:35\u201342. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2018.10.008","journal-title":"Neuropsychologia"},{"key":"1532_CR57","doi-asserted-by":"publisher","first-page":"729457","DOI":"10.3389\/fpsyt.2021.729457","volume":"12","author":"SM Levine","year":"2021","unstructured":"Levine SM, Schwarzbach JV (2021) Individualizing representational similarity analysis. Front Psychiatry 12:729457. https:\/\/doi.org\/10.3389\/fpsyt.2021.729457","journal-title":"Front Psychiatry"},{"key":"1532_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.conb.2015.12.004","volume":"36","author":"S Hong","year":"2016","unstructured":"Hong S, Dissing-Olesen L, Stevens B (2016) New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 36:128\u2013134. https:\/\/doi.org\/10.1016\/j.conb.2015.12.004","journal-title":"Curr Opin Neurobiol"},{"key":"1532_CR59","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B et al (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131:1164\u20131178. https:\/\/doi.org\/10.1016\/j.cell.2007.10.036","journal-title":"Cell"},{"key":"1532_CR60","doi-asserted-by":"publisher","first-page":"e105380","DOI":"10.15252\/embj.2020105380","volume":"9","author":"N Scott-Hewitt","year":"2020","unstructured":"Scott-Hewitt N, Perrucci F, Morini R, Erreni M, Mahoney M, Witkowska A, Carey A, Faggiani E, Schuetz LT, Mason S et al (2020) Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia. EMBO J 9:e105380. https:\/\/doi.org\/10.15252\/embj.2020105380","journal-title":"EMBO J"},{"key":"1532_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature12776","volume":"504","author":"WS Chung","year":"2013","unstructured":"Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson AC et al (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504:394\u2013400. https:\/\/doi.org\/10.1038\/nature12776","journal-title":"Nature"},{"key":"1532_CR62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41586-020-03060-3","volume":"590","author":"JH Lee","year":"2021","unstructured":"Lee JH, Kim JY, Noh S, Lee H, Lee SY, Mun JY, Park H, Chung WS (2021) Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis. Nature 590:612\u2013617. https:\/\/doi.org\/10.1038\/s41586-020-03060-3","journal-title":"Nature"},{"key":"1532_CR63","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, RamakrishnanS MKM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352:712\u2013716. https:\/\/doi.org\/10.1126\/science.aad8373","journal-title":"Science"},{"key":"1532_CR64","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00406-021-01273-9","volume":"271","author":"C Rupprecht","year":"2021","unstructured":"Rupprecht C, Rupprecht R, Rammes G (2021) C1q, a small molecule with high impact on brain development: putative role for aging processes and the occurrence of Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 271:809\u2013812. https:\/\/doi.org\/10.1007\/s00406-021-01273-9","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1532_CR65","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1111\/ejn.14900","volume":"54","author":"C Roman","year":"2020","unstructured":"Roman C, Egert L, Di Benedetto B (2020) Astrocytic-neuronal crosstalk gets jammed: alternative perspectives on the onset of neuropsychiatric disorders. Eur J Neurosci 54:5717\u20135729. https:\/\/doi.org\/10.1111\/ejn.14900","journal-title":"Eur J Neurosci"},{"key":"1532_CR66","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1523\/JNEUROSCI.3932-10.2011","volume":"31","author":"E Benoit","year":"2011","unstructured":"Benoit E, Tenner AJ (2011) Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 31:3459\u20133469. https:\/\/doi.org\/10.1523\/JNEUROSCI.3932-10.2011","journal-title":"J Neurosci"},{"key":"1532_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/a-1704-8260","volume":"55","author":"C Rupprecht","year":"2022","unstructured":"Rupprecht C, Sarker RSJ, Rammes G (2022) Morphological representation of C1q in the aging central nervous system. Pharmacopsychiatry 55:203\u2013210. https:\/\/doi.org\/10.1055\/a-1704-8260","journal-title":"Pharmacopsychiatry"},{"key":"1532_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000051265","volume":"12","author":"I Tooyama","year":"2001","unstructured":"Tooyama I, Sato H, Yasuhara O, Kimura H, Konishi Y, Shen Y, Walker DG, Beach TG, Sue LI, Rogers J (2001) Correlation of the expression level of C1qmRNA and the number of C1q-positive plaques in the Alzheimer disease temporal cortex. Analysis of C1q mRNA and its protein using adjacent or nearby sections. Dement Geriatr Cogn Disord 12:237\u2013242. https:\/\/doi.org\/10.1159\/000051265","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1532_CR69","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4103\/psychiatry.IndianJPsychiatry_394_19","volume":"62","author":"J Yang","year":"2020","unstructured":"Yang J, Li R, Shi Y, Jiang S, Liu J (2020) Is serum complement C1q related to major depressive disorder? Indian J Psychiatry 62:659\u2013663. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_394_19","journal-title":"Indian J Psychiatry"},{"key":"1532_CR70","doi-asserted-by":"publisher","first-page":"110105","DOI":"10.1016\/j.jpsychores.2020.110105","volume":"133","author":"Q Yao","year":"2020","unstructured":"Yao Q, Li J (2020) Increased serum levels of complement C1q in major depressive disorder. J Psychosom Res 133:110105. https:\/\/doi.org\/10.1016\/j.jpsychores.2020.110105","journal-title":"J Psychosom Res"},{"key":"1532_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12974-021-02122-1","volume":"18","author":"LH Fairley","year":"2021","unstructured":"Fairley LH, Sahara N, Aoki I, Ji B, Suhara T, Higuchi M, Barron AM (2021) Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy. J Neuroinflammation 18:76. https:\/\/doi.org\/10.1186\/s12974-021-02122-1","journal-title":"J Neuroinflammation"},{"key":"1532_CR72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12974-022-02573-0","volume":"19","author":"EL van der Ende","year":"2022","unstructured":"van der Ende EL, Heller C, Sogorb-Esteve A, Swift IJ, McFall D, Peakman G, Bouzigues A, Poos JM, Jiskoot LC, Panman JL et al (2022) Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study. J Neuroinflammation 19:217. https:\/\/doi.org\/10.1186\/s12974-022-02573-0","journal-title":"J Neuroinflammation"},{"key":"1532_CR73","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/brain\/awab382","volume":"145","author":"EL van der Ende","year":"2022","unstructured":"van der Ende EL, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Wilke C, Synofzik M et al (2022) A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain 145:1805\u20131817. https:\/\/doi.org\/10.1093\/brain\/awab382","journal-title":"Brain"},{"key":"1532_CR74","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2021.12.016","volume":"110","author":"F Brosseron","year":"2022","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Gonz\u00e1lez PG, McManus RM, Ising C, Santarelli F, Kolbe CC, H\u00e4sler LM et al (2022) Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer\u2019s disease. Neuron 110:1009\u20131022. https:\/\/doi.org\/10.1016\/j.neuron.2021.12.016","journal-title":"Neuron"},{"key":"1532_CR75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41593-022-01013-9","volume":"25","author":"Y Shi","year":"2022","unstructured":"Shi Y, Cui M, Ochs K, Str\u00fcbing FL, Briel N, Eckenweber F et al (2022) Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO). Nat Neurosci 25:317\u2013329. https:\/\/doi.org\/10.1038\/s41593-022-01013-9","journal-title":"Nat Neurosci"},{"key":"1532_CR76","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0887-6177(03)00096-9","volume":"19","author":"M Barker","year":"2004","unstructured":"Barker M, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437\u2013454. https:\/\/doi.org\/10.1016\/S0887-6177(03)00096-9","journal-title":"Arch Clin Neuropsychol"},{"key":"1532_CR77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WAD.0000000000000099","volume":"30","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhou X, Meranus DH, Wang L, Kukull WA (2016) Benzodiazepine use and cognitive decline in elderly with normal cognition. Alzheimer Dis Assoc Disord 30:113\u2013117. https:\/\/doi.org\/10.1097\/WAD.0000000000000099","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1532_CR78","doi-asserted-by":"publisher","first-page":"g5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"SB de Gage","year":"2014","unstructured":"de Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M et al (2014) Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. Br Med J 349:g5205\u2013g5205. https:\/\/doi.org\/10.1136\/bmj.g5205","journal-title":"Br Med J"},{"key":"1532_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40263-016-0404-x","volume":"31","author":"FA Bi\u00e9try","year":"2017","unstructured":"Bi\u00e9try FA, Pfeil AM, Reich O, Schwenkglenks M, Meier CR (2017) Benzodiazepine use and risk of developing Alzheimer\u2019s disease: a case-control study based on Swiss claims data. CNS Drugs 31:245\u2013251. https:\/\/doi.org\/10.1007\/s40263-016-0404-x","journal-title":"CNS Drugs"},{"key":"1532_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i90","volume":"352","author":"SL Gray","year":"2016","unstructured":"Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA et al (2016) Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. Br Med J 352:i90. https:\/\/doi.org\/10.1136\/bmj.i90","journal-title":"Br Med J"},{"key":"1532_CR81","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/ALN.0000000000004202","volume":"136","author":"X Puig-Bosch","year":"2022","unstructured":"Puig-Bosch X, Bieletzki S, Zeilhofer HU, Rudolph U, Antkowiak B, Rammes G (2022) Midazolam at low nanomolar concentrations affects long-term potentiation and synaptic transmission predominantly via the \u03b11-\u03b3-aminobutyric acid type a receptor subunit in mice. Anesthesiology 136:954\u2013969. https:\/\/doi.org\/10.1097\/ALN.0000000000004202","journal-title":"Anesthesiology"},{"key":"1532_CR82","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028019873320","volume":"54","author":"JG Powell","year":"2020","unstructured":"Powell JG, Garland S, Preston K, Piszczatoski C (2020) Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression. Ann Pharmacother Actions 54:157\u2013163. https:\/\/doi.org\/10.1177\/1060028019873320","journal-title":"Ann Pharmacother Actions"},{"key":"1532_CR83","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","volume":"390","author":"S Kanes","year":"2017","unstructured":"Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S (2017) Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390:480\u2013489. https:\/\/doi.org\/10.1016\/S0140-6736(17)31264-3","journal-title":"Lancet"},{"key":"1532_CR84","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Calquhoun H, Riesenberg R, Epperson CN, Deligiannidis K, Rubinow DR, Li H, Sankah AS, Glemson C, Schacterle A, Jonas J et al (2018) Brexanolone injection in post-partum depression: two multicentre, double blind, randomised, placebo-controlled, phase-3 trails. Lancet 392:1058\u20131070. https:\/\/doi.org\/10.1016\/S0140-6736(18)31551-4","journal-title":"Lancet"},{"key":"1532_CR85","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12887","author":"LE Dichtel","year":"2020","unstructured":"Dichtel LE, Nyer M, Dording C, Fisher LB, Cusin C, Shapero BG, Pedrelli P, Kimball AS, Rao EM, Mischoulon D, Fava M, Miller KK (2020) Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: a pilot study. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.19m12887","journal-title":"J Clin Psychiatry"},{"key":"1532_CR86","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"H Gunduz-Bruce","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ (2019) Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381:903\u2013911. https:\/\/doi.org\/10.1056\/NEJMoa1815981","journal-title":"N Engl J Med"},{"key":"1532_CR87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2022.03.068","volume":"308","author":"E Suthoff","year":"2022","unstructured":"Suthoff E, Kosinski M, Arnaud A, Hodgkins P, Gunduz-Bruce H, Lasser R, Silber C, Sankoh AJ, Li H, Werneburg B, Jonas J, Doherty J, Kanes SJ, Bonthapally V (2022) Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. J Affect Disord 308:19\u201326. https:\/\/doi.org\/10.1016\/j.jad.2022.03.068","journal-title":"J Affect Disord"},{"key":"1532_CR88","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","volume":"285","author":"A Arnaud","year":"2021","unstructured":"Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O\u2019Day K (2021) Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord 285:112\u2013119. https:\/\/doi.org\/10.1016\/j.jad.2021.02.027","journal-title":"J Affect Disord"},{"key":"1532_CR89","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78:951\u2013959. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"key":"1532_CR90","doi-asserted-by":"publisher","first-page":"e2806","DOI":"10.1002\/hup.2806","volume":"37","author":"A Bullock","year":"2022","unstructured":"Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, Silber C, Kanes SJ, Jonas J, Doherty J (2022) A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol 37:e2806. https:\/\/doi.org\/10.1002\/hup.2806","journal-title":"Hum Psychopharmacol"},{"key":"1532_CR91","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","volume":"113","author":"C Sch\u00fcle","year":"2014","unstructured":"Sch\u00fcle C, Nothdurfter C, Rupprecht R (2014) The role of allopregnanolone in depression and anxiety. Prog Neurobiol 113:79\u201387. https:\/\/doi.org\/10.1016\/j.pneurobio.2013.09.003","journal-title":"Prog Neurobiol"},{"key":"1532_CR92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","volume":"60","author":"G Rammes","year":"2011","unstructured":"Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60:982\u2013990. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.051","journal-title":"Neuropharmacology"},{"key":"1532_CR93","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuropharm.2014.12.037","volume":"92","author":"G Rammes","year":"2015","unstructured":"Rammes G, Gravius A, Ruitenberg M, Wegener N, Chambon C, Sroka-Saidi K, Jeggo R et al (2015) MRZ-99030\u2013A novel modulator of A\u03b2 aggregation: II - Reversal of A\u03b2 oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. Neuropharmacology 92:170\u2013182. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.12.037","journal-title":"Neuropharmacology"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01532-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T05:03:37Z","timestamp":1693285417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01532-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01532-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RR has received consultancy honoraria from SAGE\/Biogen and GABA Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}